1. Characterization of residual microRNAs in AAV vector batches produced in HEK293 mammalian cells and Sf9 insect cells
- Author
-
Magalie Penaud-Budloo, Emilie Lecomte, Quentin Lecomte, Simon Pacouret, Frédéric Broucque, Aurélien Guy-Duché, Jean-Baptiste Dupont, Laurence Jeanson-Leh, Cécile Robin, Véronique Blouin, Eduard Ayuso, and Oumeya Adjali
- Subjects
gene therapy ,AAV vectors ,bioproduction ,quality control ,residual nucleic acids ,microRNA ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
With more than 130 clinical trials and 8 approved gene therapy products, adeno-associated virus (AAV) stands as one of the most popular vehicles to deliver therapeutic DNA in vivo. One critical quality attribute analyzed in AAV batches is the presence of residual DNA, as it could pose genotoxic risks or induce immune responses. Surprisingly, the presence of small cell-derived RNAs, such as microRNAs (miRNAs), has not been investigated previously. In this study, we examined the presence of miRNAs in purified AAV batches produced in mammalian or in insect cells. Our findings revealed that miRNAs were present in all batches, regardless of the production cell line or capsid serotype (2 and 8). Quantitative assays indicated that miRNAs were co-purified with the recombinant AAV particles in a proportion correlated with their abundance in the production cells. The level of residual miRNAs was reduced via an immunoaffinity chromatography purification process including a tangential flow filtration step or by RNase treatment, suggesting that most miRNA contaminants are likely non-encapsidated. In summary, we demonstrate, for the first time, that miRNAs are co-purified with AAV particles. Further investigations are required to determine whether these miRNAs could interfere with the safety or efficacy of AAV-mediated gene therapy.
- Published
- 2024
- Full Text
- View/download PDF